Skip to main content

Scilex Holding Co

SCLX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001820190

No open-market purchases or sales by Scilex Holding Co insiders were filed in the last 90 days; 73 institutions reported holding it in 13F filings for Q2 2026, worth $5.48M in total; no superinvestor holds it.

Other share classesSCLXW

Q4 2025 vs. Q3 2025

How the institutions holding Scilex Holding Co changed between Q3 2025 and Q4 2025.

All holders in Q4 2025All holders in Q3 2025

13F holders of SCLX: Q3 2025 compared with Q4 2025
MeasureQ3 2025Of which not filed for Q4 2025Q4 2025Change
Holders831820
Shares759.9K11.9K1.12M+371.8K (+49.7%)
Value$15.0M$233.7K$13.7M−$1.07M (−7.3%)

1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (11)

Institutions that held Scilex Holding Co at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to SCLX in Q4 2025
InstitutionSharesValue% of portfolio
683 Capital Management, LLC27,312$333.2K0.03%
XTX Topco Ltd20,444$249.4K0.01%
Citigroup Inc19,846$242.1K0.00%
Omers Administration Corp12,300$150.1K0.00%
Qube Research & Technologies Ltd11,575$141.2K0.00%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.3,119$38.0K0.00%
Cornerstone Financial Management LLC26$3170.00%
Tidemark, LLC4$490.00%
International Assets Investment Management, LLC3$370.00%
SageView Advisory Group, LLC2$260.00%
Investors Portfolio Services LLC2$250.00%

Sold out (11)

Institutions that held Scilex Holding Co at the end of Q3 2025 and filed for Q4 2025 without it.

Not filed for Q4 2025 yet (1)

Institutions that held Scilex Holding Co at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding SCLX in Q3 2025 that haven't filed for Q4 2025
InstitutionShares, Q3 2025Value, Q3 2025
Donald L. Hagan, LLC11,873$233.7K